The efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy for locally advanced gastric cancer: a single-center, real-world clinical study
Here, neoadjuvant immunochemotherapy suggested a potential clinical benefit of the pCR rate, T downstaging, and a favorable safety profile for LAGC. However, further multicenter, large-scale randomized clinical trials are urgently needed to confirm the long-term survival benefit.
Authors
- Pingping Wu (ORCID: https://orcid.org/0000-0001-5820-6413)
- Chao Yue (ORCID: https://orcid.org/0000-0001-9720-5210)
- Shuchen Dong (ORCID: https://orcid.org/0000-0002-2179-0414)
- Siwen Liu (ORCID: https://orcid.org/0000-0002-0446-0448)
- Xuan Pan (ORCID: https://orcid.org/0000-0001-9161-4267)
- Yan Sun
- Huayun Zhu
- Xingwang Li (ORCID: https://orcid.org/0000-0002-5903-2774)
Institutions
- Jiangsu Cancer Hospital (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-09-18
- DOI
- https://doi.org/10.1007/s00262-025-04153-6
- Citations
- 3
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 4.56
Funders
- National Natural Science Foundation of China
- Wu Jieping Medical Foundation
- Jiangsu Cancer Hospital